search
Front

BiolineRX to develop diabetes treatment

23 Aug, 2010 15:00
שלח תגובה במיילShiri Habib-Valdhorn

EDP-01 is its first success in the program to test drugs that haven't been in animal trials.

BiolineRX Ltd. (TASE:BLRX) is expanding its product pipeline by developing a new molecule for the treatment of diabetes.

The drug development company today announced that the new drug EDP-01 for diabetes is the first success of its EDP program for developing innovative projects from the earliest stages. The aim of the EDP program, which was begun in 2007, is to identify and promote promising research that has not yet been tested on animals.

BiolineRX is currently developing 11 treatments and already has two commercialization deals for a schizophrenia treatment and a heart disease treatment. At the same time, the company is investigating 9 molecules as part of the EDP program.

The EDP-01 molecule was discovered by Prof. Bilha Fischer of Bar Ilan University's Department of Chemistry. Animal trials over the past two years have shown that the molecule can lower high levels of sugar in the blood and it is felt that the drug has potential for treating type II diabetes.

EDP-01, which will now be known as BL-6010 is an enzymatically-stable purine receptor agonist that promotes insulin secretion in the presence of glucose by a novel mechanism. The rights have been acquired from Bar Ilan University's R&D company BIRAD.

BiolineRX recently received $30 million from Cypress Bioscience, Inc. (Nasdaq: CYPB) for an out-licensing agreement for its BL-1020 drug for treating schizophrenia.

BiolineRX's share was up 1.4% to NIS 3.43 in afternoon trading on the TASE, giving a market cap of NIS 424 million.

Published by Globes, Israel business news - www.globes-online.com - on August 23, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

US President Donald Trump credit: Reuters Sipa USA Israel on list as Trump unveils tariffs

Relatively low reciprocal tariffs will be imposed on Israeli goods sold in the US.

Minister of Finance Bezalel Smotrich credit: Shlomi Yosef OECD sees recovery in growth but high inflation

The OECD Israel Economic Survey 2025 recommends that the Israeli government take several restraining measures, in order to exit the economic storm created by the war.

Deflated unicorn credit: Shutterstock Big Tech 50 reports more huge falls in startup valuations

Israeli R&D partnership Big Tech 50 reports that an investment of $2 million in Orcam made in 2021, shrank to just $31,000 at the end of 2024.

Dano Ben-Hur credit: Dror Sithakol Statisticians contradict BoI on impact of housing finance deals

The Central Bureau of Statistics insists the impact of 20/80 buy now pay later financing deals on the real estate market and housing prices is minimal.

APM merges with lawyers from Doron, Tikotzky Kantor, Gutman credit: Eyal Merilos APM merges with 12 lawyers from Doron, Tikotzky Kantor, Gutman

With the addition of these 12 lawyers, Amit Pollak Matalon & Co. will now have 135 lawyers.

NextFerm technologies based on yeast credit: NextFerm Food-tech co NextFerm suspends operations

The company, which produces food ingredients in yeast without genetic engineering, cannot pay its debts and is seeking a buyer.

Wed: Banks lead strong TASE gains

Delek, Nova and the banks led the market higher today but Teva lost ground.

Analysts see Israel-linked Nebius challenging CoreWeave

Nebius, founded by Yandex founder Arkady Volozh, operates in CoreWeave's AI server market, but is growing "more rationally", and has far less debt.

Elbit Systems rocket launcher credit: Elbit Systems Elbit Systems wins $130m European rocket order

The order is for the supply of rockets for Elbit's Precise and Universal Launching System (PULS), which has an effective range of up to 300 kilometers.

Highcon chairperson Shlomo Nimrodi credit: PR Packaging tech co Highcon winding down

The company, which numbers Benny Landa and JVP among its investors, is laying off most of its workforce, having lost 99.9% of its value since its flotation.

Big banks CEOs credit: Oren Dai, Jonthan Bloom and Israel Hadari Israeli banks unveil NIS 3b customer benefits package

The benefits over two years meet the target set by the Bank of Israel to ease the burden for customers, while the banks are reporting record profits.

Record public company profits credit: Tali Bogdanovsky Profits peak, but reckoning awaits

In what may seem a paradox, profits grew in almost every sector on the Tel Aviv Stock Exchange last year, but the boom was largely fueled by government spending.

Tel Aviv Stock Exchange credit: PR Volumes peak on Tel Aviv Stock Exchange

Greater optimism in Israel and a shift away from US markets have brought trading volumes in Tel Aviv to a historical high, but will the trend be sustained?

Ishay Davidi credit: Cadya Levy FIMI CEO: Foreign investors flocking back to Israel

Ishay Davidi told the Globes "Going Long on Israel" Conference that investors who pulled out of Israel after October 7 have begun returning in large numbers.

US President Donald Trump credit: Reuters/Leah Millis Israel moves to avoid Trump's tariffs axe

Minister of Finance Bezalel Smotrich has signed an order canceling all tariffs on imports from the US. The impact will mostly be on agricultural produce.

Governor of the Bank of Israel Amir Yaron credit: Government Press Office Debt fears top Bank of Israel's concerns

Most unusually, Governor of the Bank of Israel Amir Yaron's press conference last week did not focus on inflation and the impending interest rate decision.

Forbes Rich List credit: Shutterstock Maslowski Marcin Wiz founders ranked in Forbes 2025 Rich List

There are a few dozen Israelis listed in the 2025 Forbes Real-Time Billionaires List including Wiz founders Assaf Rappaport, Yinon Costica, Roy Reznik and Ami Luttwak.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018